Page last updated: 2024-11-13
sphingadienine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 22015051 |
MeSH ID | M0044372 |
Synonyms (2)
Synonym |
---|
25696-03-1 |
sphingadienine , |
Research Excerpts
Bioavailability
4,8-sphingadienine is poorly absorbed in the intestine because of efflux by P-glycoprotein. It can be incorporated into a ceramide moiety, at least in part, in intestinal endothelial cells.
Excerpt | Reference | Relevance |
---|---|---|
" Isomers of 4,8-sphingadienine degraded from dietary plant cerebrosides appear to be poorly absorbed from the digestive tract." | ( Digestion of maize sphingolipids in rats and uptake of sphingadienine by Caco-2 cells. Kinoshita, M; Nagata, J; Ohnishi, M; Saito, M; Sugawara, T, 2003) | 0.91 |
" These results indicate that 4,8-sphingadienine that originates from the glucosylceramide of higher plants is poorly absorbed in the intestine because of efflux by P-glycoprotein and can be incorporated into a ceramide moiety, at least in part, in intestinal endothelial cells." | ( Selective Absorption of Dietary Sphingoid Bases from the Intestine via Efflux by P-Glycoprotein in Rats. Aida, K; Fujii, A; Hirata, T; Manabe, Y; Sugawara, T; Tsuduki, T, 2017) | 0.74 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (19)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (5.26) | 18.2507 |
2000's | 3 (15.79) | 29.6817 |
2010's | 10 (52.63) | 24.3611 |
2020's | 5 (26.32) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 21.57
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.57) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 19 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |